ReviewGene therapy2007
Progress and prospects: RNA-based therapies for treatment of HIV infection.
Review in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 80 citations in OpenAlex.
- Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.IET nanobiotechnology · 2022Review
- CRISPR-Cas13a Inhibits HIV-1 Infection.Molecular therapy. Nucleic acids · 2020Article
- Kinases: Understanding Their Role in HIV Infection.World journal of AIDS · 2019Article
- Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Chemistry & biology · 2015Article
- Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2014Review
- Article
- Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV.Infectious diseases in obstetrics and gynecology · 2014Review
- Aptamer-based therapeutics: new approaches to combat human viral diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy.Nanoscale research letters · 2013Article
- Digoxin suppresses HIV-1 replication by altering viral RNA processing.PLoS pathogens · 2013Article
- Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer.Nanoscale research letters · 2012Article
- Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2012Review
- Article
- Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Current progress in the development of RNAi-based therapeutics for HIV-1.Gene therapy · 2011Review
- RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.The Yale journal of biology and medicine · 2011Review
- Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.Methods (San Diego, Calif.) · 2011Article
- Article
- Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes.Nano letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment regimen for HIV-infected individuals combines two or more drugs targeting different viral proteins such as RT and gag. Resistance to conventional drugs can develop quickly, and typically persists. The prospect of longer, continuous antiretroviral therapy brings with it the need for new antiretroviral drugs and approaches. In this context, gene therapies have the potential to prolong life and quality of life as an additional therapeutic class and may serve as an adjuvant to traditional treatments. This review focuses on RNA-based hematopoietic cell gene therapy for treatment of HIV infection. Recent advances in our understanding of RNA interference (RNAi) make this an especially attractive candidate for anti-HIV gene therapy although ribozyme and RNA decoy/aptamer approaches can be combined with RNAi to make a combinatorial therapy akin to highly active anti-retroviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.